A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

← catalyst calendar

NCT05329766 · readout ≤ 165 d

Sponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →. With Gilead Sciences.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

332actual

Sites

Countries

Canada, Chile, France +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-06-10

actual

When the study began enrolling

Primary completion

Jan 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jun 2027

estimated

The whole study's end, after follow-up

First posted

2022-04-15

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Gastrointestinal Tract Malignancies

Interventions

Drug: Domvanalimab
Drug: Quemliclustat
Drug: Zimberelimab
Drug: Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Adverse Events (AEs)

measured Up to 18 months

Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

measured Up to 18 months

Publications

PMID 41109921 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed